agalsidase

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

36 competitors in Fabry Disease

#DrugCompanyPhaseTrials

1

Fabrazyme (agalsidase Beta)

Sanofi

Approved

42

Active Comparator

Moderna

Phase 3

13

Venglustat

Sanofi

Phase 3

14

Farxiga

AstraZeneca

Phase 2

15

agalsidase

Sanofi

Approved

86

Recombinant Alpha-Galactosidase a

AAssistance Publique - Hôpitaux de Paris

Approved

17

Replagal

Takeda

Phase 3

118

Galafold

AAmicus Therapeutics

Phase 3

39

Agalsidase Alfa

Takeda

Phase 3

610

Migalastat Hcl

AAmicus Therapeutics

Phase 3

14Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Fabry Disease8 trials

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

Completed·AAmicus Therapeutics·Phase 2·NCT01196871·20 enrolled

Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease

Completed·AAmicus Therapeutics·Phase 3·NCT01218659·68 enrolled

A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.

Completed·Sanofi··NCT00233870·405 enrolled

Show 5 more trials

To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease

Withdrawn·Sanofi·Phase 4·NCT04143958

A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease

Completed·Sanofi·Phase 4·NCT00140621·6 enrolled

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

Recruiting·MMackay Memorial Hospital··NCT05698901·150 enrolled

A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease

Completed·Sanofi·Phase 4·NCT00081497·67 enrolled

A Randomized, Open-label, Parallel-group, 18-month Phase 3 Study to Evaluate the Effect of Venglustat Compared With Usual Standard of Care on Left Ventricular Mass Index in Participants With Fabry Disease and Left Ventricular Hypertrophy

Active, not recruiting·Sanofi·Phase 3·NCT05280548·104 enrolled

Treatment1 trial

Study of the Effects of Fabrazyme Treatment on Lactation and Infants

Terminated·Sanofi·Phase 4·NCT00230607·7 enrolled

ALS1 trial

A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta

Completed·Sanofi·Phase 4·NCT01650779·15 enrolled

Prospective1 trial

A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme

Completed·Sanofi·Phase 4·NCT06019728·8 enrolled

Pediatric Patients1 trial

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

Completed·Sanofi·Phase 3·NCT00701415·31 enrolled

2 more indications

Safety and Efficacy1 trial

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

Completed·PProtalix·Phase 3·NCT02795676·78 enrolled

Unspecified1 trial

China Post-marketing Surveillance (PMS) Study of Fabrazyme®

Completed·Sanofi·Phase 4·NCT05054387·22 enrolled

Details

Drug Info

Related News